Medicis, the American pharmaceutical that brought us Restylane, Perlane and Dysport, recently announced FDA approval for a non-surgical body slimming procedure called “Liposonix.” But the company doesn’t plan to market the treatment in the U.S.
Liposonix is a new treatment that uses high-intensity, focused ultrasound to eliminate fat that is just beneath the skin. The company reportedly received FDA approval for “non-invasive waist circumference reduction.”
In a press release issued Thursday morning, the company stated:
Medicis is not planning to launch the LIPOSONIX system in the U.S., and would anticipate that plans for a U.S. launch will be announced by an acquiring company, if any, if and when such acquiring company deems appropriate.
The treatment is available in Canada, Japan and Europe. Although the procedure is officially cleared for sale in the U.S., people interested in it may need to wait until another company acquires the rights to market Liposonix technology from Medicis.
Medicis is best known for providing high quality injectable products, including Restylane and Perlane, some of the world’s most popular wrinkle fillers; and Dysport, the injectable botulinum toxin medication that works in a similar manner to Botox Cosmetic.